Evidence map›Paper›PMID 39592650›Full record

ArticleScientific reports2024

Molecular mechanisms impact on fluoroquinolone resistance among E.coli from enteric carriage monitoring before prostate biopsy and earliest description of qnrB81.

Rehaiem Amel, Bouzouita Abderrazek, Ferjani Sana, Saadi Ahmed, Zrelli Mariem, Kanzari Lamia, Ferjani Asma, Mohamed Riadh Ben Slama, Boutiba Ben Boubaker Ilhem

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Repurposing of Furin Inhibitors to Reduce PathogenicAntibiotics (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Rehaiem AmelFaculty of Medicine of Tunis - LR99ES09 Research Laboratory «Antimicrobial resistance», University of Tunis El Manar, 1007, Tunis, Tunisia. rehaiem_amel@yahoo.fr.ORCID http://orcid.org/0000-0001-7245-1976
Bouzouita AbderrazekFaculty of Medicine of Tunis - LR99ES09 Research Laboratory «Antimicrobial resistance», University of Tunis El Manar, 1007, Tunis, Tunisia.
Ferjani SanaFaculty of Medicine of Tunis - LR99ES09 Research Laboratory «Antimicrobial resistance», University of Tunis El Manar, 1007, Tunis, Tunisia.
Saadi AhmedCharles Nicolle Hospital, Urology ward, 1006, Tunis, Tunisia.
Zrelli MariemFaculty of Medicine of Tunis - LR99ES09 Research Laboratory «Antimicrobial resistance», University of Tunis El Manar, 1007, Tunis, Tunisia.
Kanzari LamiaFaculty of Medicine of Tunis - LR99ES09 Research Laboratory «Antimicrobial resistance», University of Tunis El Manar, 1007, Tunis, Tunisia.
Ferjani AsmaFaculty of Medicine of Tunis - LR99ES09 Research Laboratory «Antimicrobial resistance», University of Tunis El Manar, 1007, Tunis, Tunisia.
Mohamed Riadh Ben SlamaCharles Nicolle Hospital, Urology ward, 1006, Tunis, Tunisia.
Boutiba Ben Boubaker IlhemFaculty of Medicine of Tunis - LR99ES09 Research Laboratory «Antimicrobial resistance», University of Tunis El Manar, 1007, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fluoroquinolone-resistant (FQs-R) microorganisms causing infectious complications after ultrasound-guided needle biopsy of the prostate (TRUS-BP) have become an important challenge in healthcare settings globally, questioning the continued utility of FQ as the preferred prophylactic agent. This study aimed to characterize molecular mechanisms of resistance on FQs-R E. coli isolated from the enteric microbiota of patients undergoing (TRUS-BP) and to highlight their impact on Minimum Inhibitory Concentrations (MICs). From February 2016 to December 2018, the incidence of rectal carriage of Qs-FQs resistant Enterobacterales detected from rectal swabs of patients before undergoing (TRUS-BP) was 61.06% (80/131) all related to E. coli species. Based on the MICs range of Qs (24-256 mg/L) and FQs (0.24-128 mg/L) breakpoint by EUCAST, we categorized these E. coli isolates into three resistance profiles (I, II, and III) associated with the patterns of chromosomal mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC and the plasmid-mediated quinolone resistance encoding genes (PMQRs) detected by PCR-based assay and sequencing; MICs increase in an escalation step according to the co-occurrence of multiple molecular mechanisms. The mutation of the gyrA gene was the most frequent on codons (Ser83Leu/Thr/Tyr/Trp and Asp87Asn); mutation on the parC gene was the least on codons (Ser80Iso/Leu and Glu84 Val/Gly/Lys). PMQRs genes (4 qnrB ,7 qnrS, and one aac(6')-Ib-cr) were determined within 15% of the isolates. Allelic variation allows us to report earliest the qnrB81 determinant in an E. coli isolate. Among isolates (35%) belonged to the notorious ST131 lineage. The phylogenetic group showed a predominance of B2 group (51, 25%), however (PFGE) revealed a high level of clonal variability. Worrying incidence of FQs-R E. coli isolates in the rectal flora of our local population showed the potential to cause post-infection. FQ resistance is a complex interplay between mutations in the QRDRs and PMQR determinants that impact MICs. The importance of intestinal microbiota as a reservoir of resistant strains and pandemic clones encourages driving mitigation challenges to characterize molecular mechanisms of antimicrobial resistance to adapt prophylactic therapy, control infection, and ensure epidemiological monitoring.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialEscherichia coliFluoroquinolonesMicrobial Sensitivity TestsProstateAgedDNA GyraseEscherichia coli InfectionsEscherichia coli ProteinsHumansMaleMutationPlasmidsAnti-Bacterial AgentsDNA GyraseEscherichia coli ProteinsFluoroquinolonesEscherichia coliFluoroquinolone resistanceMICs rectal floraPMQRs geneProstate biopsyQRDRs mutation

Identifiers

PMID39592650
PMCPMC11599381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.